Veracyte, Inc. Veracyte, Inc.

Veracyte, Inc.

VCYT

Rangering i aksjer #4288
Veracyte, Inc. operates as a diagnostics company in the United States and... Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Aksjekurs
$45.95
Markedsverdi
$3.69B
Endring (1 dag)
2.58%
Endring (1 år)
27.28%
Land
US
Handel Veracyte, Inc. (VCYT)

Kategori

Healthcare
Inntekter for Veracyte, Inc. (VCYT)
Inntekter i Jun 2026 TTM: $561.90M
Ifølge de nyeste økonomiske rapportene til Veracyte, Inc. er selskapets nåværende inntekter (TTM) $561.90M. I 2023 hadde selskapet inntekter på $361.05M en økning sammenlignet med inntektene i 2022, som var $296.54M. Inntektene er det totale beløpet et selskap genererer fra salg av varer eller tjenester. I motsetning til fortjeneste trekkes ingen kostnader fra.
Inntektshistorikk for Veracyte, Inc. fra 2011 til 2026
Inntekter ved slutten av hvert år
År Inntekter Endre
2026 (TTM) $561.90M 26.05%
2024 $445.76M 23.46%
2023 $361.05M 21.76%
2022 $296.54M 35.09%
2021 $219.51M 86.85%
2020 $117.48M -2.40%
2019 $120.37M 30.82%
2018 $92.01M 27.87%
2017 $71.95M 10.55%
2016 $65.09M 31.48%
2015 $49.50M 29.62%
2014 $38.19M 74.51%
2013 $21.88M 88.20%
2012 $11.63M 339.62%
2011 $2.65M 0.00%
Inntekter for lignende selskaper eller konkurrenter
Selskap Inntekter Forskjell i inntekter Land
$46.34B 8,146.31%
US
$25.11B 4,368.23%
US
$2.71B 381.77%
US
- -
CN
$7.37B 1,211.98%
US